Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Jan;12(1):155-8.
doi: 10.1200/JCO.1994.12.1.155.

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

R M Goldberg  1 , C L Loprinzi, J R O'Fallon, M H Veeder, A W Miser, J A Mailliard, J C Michalak, A M Dose, K M Rowland Jr, N L Burnham
Affiliations
Clinical Trial

Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

R M Goldberg et al. J Clin Oncol. 1994 Jan.

Erratum in

  • J Clin Oncol 1996 Aug;14(8):2411

Abstract

Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer.

Patients and methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study.

Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot-flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05).

Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

PubMed Disclaimer

Publication types

LinkOut - more resources